Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
Clinical trial NCT05578170 · UNKNOWN
Trial details
- NCT number
- NCT05578170
- Sponsor
- Nanfang Hospital, Southern Medical University
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2022-06-01
- Primary completion
- 2023-12-31
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.